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Abstract: The need to develop new antimicrobials is at the forefront of medical research. The notion of isolating novel an-
tifungal drugs from plant sources has become increasingly popular. The approach of using ethnobotanical information to
identify compounds with antifungal activity is of particular interest as these remedies have been used by traditional healers
for thousands of years with little or no adverse side effects. Although once a laborious task, the separation, identification
and determination of mode(s) of action of plant-derived antifungals has now become more rapid and efficient due to several
new advancements in technology. Novel assays to determine the effect(s) of plant extracts on components of metabolic
pathways are being developed. Large-scale methods to examine the pathways affected or cellular responses to a drug's
presence such as GDA (Gene Deletion Arrays) and DNA microarrays, and the limitations of such techniques are critically
examined. Coupled with analytical chemistry techniques, array-based bioassays are important for high-throughput modern
drug research. Due to the enormous diversity of plant sources that may yield antifungal drugs, a database accessible to the
scientific community containing traditional healer identified plants is recommended to increase the amount of research into
new antifungal drugs.
Keywords: Antifungal Drugs, Microarray Analysis, Genome Arrays, Traditional Medicines
Introduction
ALTHOUGH SEVERAL ANTIFUNGALdrugs exist, new antifungals are neededsince the incidence of drug resistant patho-
genic fungi appears to be increasing [1]. In
part, this increasemay be due to increases in numbers
of patients with compromised immune systems, such
as individuals undergoing chemotherapy and AIDS
patients, that may provide an infection corridor into
the human host. However, fungi have a long history
of causing animal, including human, mycoses and
the reliance on relatively few antifungals has likely
also selected for resistant pathogens. Therefore, as
is true for antimicrobial compounds in general, the
need to identify novel antifungals is of high priority.
For centuries, plants or plant derivatives have been
used in traditional medical treatments. For example,
eastern North America is host to roughly 400 species
that have been used by First Nation’s peoples as
traditional medicines [2].Plants with a history of
traditional uses in treating infections for more than
50 years, which produce few adverse reactions and
have no toxicological problems, are suitable for de-
velopment as natural health products (NHPs) in jur-
isdictions such as Canada and Australia. Alternat-
ively, if intellectual property issues can be resolved,
they may provide effective leads towards the discov-
ery of new antifungal drugs. As fungi and animals
are phylogenetically closely related, identifying
NHPs and drugs that specifically target fungi is dif-
ficult. Many compounds that appear to be excellent
fungal inhibitors are toxic to humans and are there-
fore not fit for consumption [3].
With the advent of new and improving technolo-
gies, the evaluation of plant-derived antifungals has
become more rapid and efficient. The discovery of
new plant-derived antifungal and antimicrobial NHPs
or drugs could potentially have an enormous impact
on health care in both developed and developing
countries. This paper will detail the process, benefits
and the technological aspects of discovering new
plant-derived antifungal medicines. The present pa-
per deals with methods to identify chemical compon-
ents and evaluate their effectiveness as antifungal
agents, as well as methods to determine a drug’s
mode of action in inhibiting fungal growth.
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An Ancient Tradition and Modern
Approaches
The concept of utilizing plants as remedies for med-
ical ailments and drug leads is a proven technology.
Thousands of papers on antimicrobial activity are
found in the published literature. Often, however,
plant derived remedies are not catalogued in easily
accessed literature, making selection of candidate
plant species for development of ethical therapeutic
products challenging.Many ethnomedicine practices
that utilize plants are still passed on by oral tradition
and direct communication with traditional healers is
required to identify useful leads [4]. Is traditional
knowledge useful in the discovery of antifungal
agents? A study by our group [5] on medicinal plants
utilized by eastern Canadian First Nations Peoples
found that plants that were mentioned most often by
traditional healers for conditions that have a fungal
origin had both the highest overall antifungal activity
and inhibited the growth of the largest proportion of
different fungal species (Figure 1). This strong pos-
itive correlation demonstrates that traditional know-
ledge and modern science can come to similar con-
clusions. Traditional knowledge rationalizes the se-
lection of candidate plants. Similarly, a study conduc-
ted on the antimicrobial activities of bark extracts
isolated from eastern North American hardwood
trees showed that those most used by First Nations
Peoples tended to have the highest antifungal activ-
ities [6]. When extracts from wood and bark were
compared, bark extracts showed higher amounts of
antifungal activity. That bark is preferred over wood
by traditional healers shows an understanding of
which plants to select as well as which plant parts
are most effective for therapy. In addition, it is likely
that healers learned to select plants with the least
severe side effects. Because of this, natural health
products, such as plant-derived antifungals with a
50-year history of safe use, can obtain regulatory
approval in several jurisdictions [7].
Intellectual property rights are an important aspect
to consider where traditionally used plant materials
are concerned. International treaties such as the 1992
Biodiversity Convention recognize the right of
countries (and indigenous groups) to control the use
of their biodiversity. However, rather than complex
compensation agreements which are difficult to ne-
gotiate and implement, people in developing coun-
tries need urgent assistance in the development and
improvement of ethical antifungal NHPs for AIDS
related infections. Besides traditional medicine, other
rational approaches can lead to antifungal discovery
in plants. Selection of taxa from very wet environ-
ments where fungi are prevalent, such as the Pacific
slope of Central America, led to the discovery of
some novel antifungal sesquiterpenes in a rare rain-
forest tree, Pleodendron costaricensis [8]. These
substances are effective against several species of
fungi includingmultidrug resistant forms ofCandida
albicans.
Figure 1: Efficacy of Traditional Knowledge. A strong, Positive correlation is observed between the numbers
of different Fungal Species inhibited by extracts of Plants and the frequency of recorded Antimicrobial usage
for same Plant by First Nations Peoples in Eastern Canada. Figure is adapted from Jones et al. (2000) [5]
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Antifungal Resistance and Emergence
of Opportunists
The apparent increase in incidence of drug resistant
fungal strains calls attention to the need for new an-
tifungal drugs [1]. To acquire drug resistance, fungi,
as well as other microbes, may implement several
different changes. Mutations may be selected that
increase activity of ABC transporter pumps to rapidly
export unrecognised substances, or xenobiotics, from
the cell [9]. Similarly toxin metabolism via cyto-
chrome P450s and phase 2 metabolism may be
altered in resistant fungi. If a particular antifungal
inhibits a specific enzyme function, mutations may
be selected such that the antifungal can no longer
interact with the protein and enzymatic function is
not compromised. Similarly, if an antifungal alters
a cellular function so that toxic substances increase
within the cell, the cell may alter its global metabol-
ism to by-pass the effected pathway and eliminate
the toxic substance using an alternate route [3]. For
example, azoles are a widely used group of antifungal
drugs that target ergosterol. Ergosterol, a functional
analogue of cholesterol that occurs in the fungal cell
membrane, is not found in animal cells making it a
prime target for antifungals. Recently, however,
several fungal strains have shown resistance to azole
drugs through various mechanisms, including muta-
tions in the ergosterol biosynthetic pathway that
eliminate the azole target [10]. Several plant-derived
antifungals are effective in inhibiting azole-resistant
Candida strains including extracts from ginger
(Zingiber officinale), and Echinacea pallida, a plant
popularised in Western society that was originally
used by First Nations Peoples in North America to
treat sore throat, mouth and septic ailments [11,12].
The development of new antifungals not only ap-
plies directly to human infections, but also has poten-
tial to effect human well-being indirectly. For ex-
ample, the presence of fungi in food and indoor en-
vironments is of increasing concern [13] and plant-
derived antifungals may have potential use as
fungistatic or fungicidal agents in these areas. For
example, Fusarium species are associated with
widespread crop losses worldwide, mycotoxin pro-
duction and humanmycoses. Many strains are resist-
ant to widely used antifungals [14] but several plant-
derived antifungals have been identified that are
active against Fusarium species, including extracts
obtained from Alpinia galanga, used by traditional
healers of the Kenyah tribe in Borneo [15]. Isolates
from the seeds of Syzygium jambolanum, a plant used
by traditional healers in India, Malaysia, Australia
and Ceylon, showed high levels of antifungal activity
against a range of fungal pathogens and opportunists,
including Aspergillus fumigatus [16]. Since many
other examples such as those detailed above exist,
the overall effectiveness of plant-derived antifungals
in inhibiting unwanted fungal growth is promising.
Figure 2: An Overview of Antifungal Drug Discovery from Plant-Derived Sources Based on Traditional
Phytomedicine Leads
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Advantages of Using Plant-Derived
Antifungals
Several advantages exist for using plants as a source
of antifungals compared to drug development from
a molecular perspective. Plants produce antifungal
and antimicrobial agents as secondary metabolites
in part to protect themselves from pathogens [17].
As fungal invaders circumvent secondary metabol-
ites, plants must develop new protection systems.
Since this arms race has continued for millions of
years, the number and variety of antifungals synthes-
ized by a plant species can vary. For example,
Echinacea species likely contain a combination of
acetylene and acetylenic isobutyl amides with diverse
antifungal activities [18]. An understanding of these
antifungal mechanisms employed by plants may lead
us to new antifungal analogues and control strategies.
Of particular interest, due to intense plant-fungal in-
teractions, some plant species have likely evolved
strategies to inhibit fungi that are difficult to over-
come by resistance mechanisms, although this hypo-
thesis remains to be tested.
To overcome resistance mechanisms, plants pos-
sess phytochemical diversity and redundancy so that
secondary metabolites may have multiple cellular
targets or they may contain multiple antifungals that
target different systems. For example, extracts from
Virola surinamensis yielded 9 different inhibitors of
fungal growth (phytochemical diversity) [19]. Al-
though the exact mechanisms by which these chem-
icals inhibit fungal growth are unknown, it is pre-
sumed that not all will target the same biochemical
process in the fungus. A suite of analogous anti-
fungals (phytochemical redundancy) that affects
multiple targets may be difficult to overcome by a
simple mutation in a fungal pathogen and the likeli-
hood of developing resistance may be minimized.
Synergistic interactions, where two or more sec-
ondarymetabolites work together to enhance activity,
are also likely common in plants. Synergy is difficult
to identify using current technology but can be ex-
tremely effective. For example, the medicinal plant
Berberis fremontii contains the effective antifungal,
berberine, and the synergist, 5`-methoxyhydnocarpin
[20]. It is postulated that 5`-methoxyhydnocarpin
inhibits xenobiotic pumps and thus enhances the ef-
ficacy of berberine. Since activation of xenobiotic
pumps results in cross-resistance to multiple inhibit-
ors, 5`-methoxyhydnocarpin could be used as a syn-
ergist to increase efficacy of several present day an-
tibiotics.
Isolation of Antifungal Extracts
Once a species has been identified as a potential lead,
isolation of an antifungal phytochemical from a se-
lected plant species conventionally involves bioas-
say-guided isolation (Figure 2), beginning with the
preparation of a crude extract. This involves taking
all, or selected, plant parts and grinding them in a
blender, or similar device, in the presence of a suit-
able solvent [e.g. 19]. In some cases, the resulting
slurry is exposed to sonication to help rupture the
plant cells and to release and solubilize compounds
[e.g. 21]. The crude extract is separated from cell
debris by filtration and tested for antifungal activity
as described below.
Disk Diffusion Assays
Once a crude extract has been prepared, its potential
anti-microbial activity may be tested through a
simple and reliable test, such as the disk diffusion
assay. This assay requires little in terms of material,
provides robust and reliable results, and can be used
to test a diversity of microbes. For this test, an agar
plate must first be inoculated with the microbe of
interest. A small absorbent paper disk is impregnated
with the plant extract to be tested and then placed
onto the surface of the agar. The extract will diffuse
into the agar medium surrounding the disk, where
any antimicrobial effects will interfere with growth
of the microbe. The concentration of the extract will
be highest near the paper disk, and decrease radially
to a point where the concentration is no longer inhib-
itory. After incubation, inhibitory activity is observed
as a region around the disk where no growth has oc-
curred, termed the zone of inhibition. The size of the
zone of inhibition is dependent on the inhibitory
compound’s ability to diffuse through the medium,
its inhibitory characteristics and abundance in the
crude extract. The zone of inhibition can be com-
pared to a similarly prepared disc containing a known
inhibitor and to a negative control disk that is pre-
pared with the solvent carrier [15]. This technique
has been used in the past to identify antifungal effects
as well as other antimicrobial activity in crude ex-
tracts from diverse plant species
[5,6,12,15,18,21,22,23,24]. The technique may be
of limited use if inhibitory compounds do not ad-
equately diffuse through the agar medium and the
zone of inhibition is obscured by the paper disk. Al-
though this test does not reveal the mechanism by
which extracts inhibit growth, it can quickly determ-
ine whether a plant extract is active against strains
that are resistant to known antibiotics [23].
Identification of Antifungal Constituents
Conventional bioassay-guided fractionation is most
often used to isolate and identify unknown antifungal
compound(s) [e.g. 12]. This process involves separ-
ating compounds based on extraction of fractions
from the plant material based on a series of solvents
of increasing polarity, such as hexane, ethyl acetate
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and methanol. The fractions are tested for activity
and the active fraction is further separated by column
chromatography. Multiple different fractions are
collected and each is subjected to further antimicro-
bial bioassays. If deemed active, a particular fraction
is further resolved by preparative HPLC until a single
active compound is isolated [12,24]. The structure
of the pure compound is then identified by advanced
spectroscopic techniques. Recently, high throughput
metabolomicsmethods such asHPLC-MS/MS assays
have been developed that can be used to identify
members of known families of compounds in plants
by matching fragmentation patterns to libraries of
known compounds.
Metabolic Assays
After isolating a compound and determining that it
has antifungal activity, several forms of assays may
be useful to elucidate the compound’s cellular tar-
get(s). Most compounds will interact with and inac-
tivate a specific enzyme, pathway, or stage in a
pathogen’s life cycle.Provided the drug interferes
with the pathogenic organism’s growth, but does not
substantially interfere with the host, any essential
component of the pathogen can be tested as a poten-
tial target site. The goal of a metabolic assay is to
test a compound for these potential effects on a spe-
cific pathway, and each assay relies on an in vitro
approximation of the pathway examined. Such assays
can take multiple formats, such as the substrate
conversion system, DNA polymerization or nucle-
otide biosynthesis.
For substrate conversion assays, the test compound
is mixed with an enzyme of interest, and the assay
is based on colourimetric, fluorescent, or radiometric
monitoring of the catalytic process. The binding of
the test compound to the enzyme may reduce the
enzyme’s ability to catalyze the substrate-to-product
reaction, and therefore alters the reaction kinetics in
comparison to a system without the test compound.
Colour or fluorescence signals can be monitored
spectrophotometrically in this assay, and radiometric
effects can be detected by scintillation counting or
using film or digital imaging techniques.
To examine DNA polymerization, nucleotides
labeled with radioactive isotopes have been used in
the past as substrate components. A proxy of DNA
replication in cells may use the polymerase chain-
reaction (PCR). Under ideal circumstances, the
amount of the DNA sequence of interest (the “ampl-
icon”) doubles during each cycle. However, the ad-
dition of a compound that interferes with DNA
polymerization would inhibit amplification, and di-
minishes the amount of newly synthesized DNA
[25]. The inhibitor may act on any component of the
PCR process, including Taq polymerase or the DNA
template.
Recently, a modification of the PCR procedure
has been developed to allow for continuous quanti-
fication of the amount of DNA synthesized during
the reaction [26]. This method of real-time PCR (RT-
PCR) presents a simple and precise approach for
measuring the quantity of amplicon produced and
the efficiency of the reaction. By comparing the rates
at which the amplicon concentration increases in
different reactions, a precise measure of the inhibit-
ory effects of an extract can be calculated.
Compounds that inhibit DNA polymerizationmay
be genotoxic to a wide variety of organisms, how-
ever, and therefore of little use as antimicrobials
geared towards medicines taken internally. However,
differences in the base composition of some micro-
bial genomes, or in the polymerase enzyme itself,
may provide specific targets [25]. Furthermore, such
compounds may have applications as topical treat-
ments or in preventing materials spoilage.
The activity of the Ribonucleotide Reductase en-
zyme (RNR), which is essential in many organisms
for the conversion of RNA precursors into DNA
precursors that are used in the replication and repair
of DNA synthesis, can be tested using radioactive
tracers. RNR converts the ribonucleoside diphosphate
into deoxyribonucleoside diphosphate, which is
subsequently phosphorylated and incorporated into
DNA by DNA polymerase. RNR catalytic activity
can thus be estimated by monitoring the amount of
a suitable radioactively labeled substrate that is incor-
porated into DNA using scintillation counting. If the
enzyme is inhibited by the addition of a specific in-
hibitor of RNR, little or no DNA polymerization will
occur and scintillation counts will be low [27]. Res-
veratrol, a chemical extracted from red grape skins,
was found to target RNR using this method [28].
Resveratrol was found to be more effective than hy-
droxyurea, p-propoxyphenol, and the clinically-used
hydroxyanisole. As this compound is found in grapes,
which are Generally Regarded As Safe (GRAS), it
or similar compounds may have potential as inhibit-
ors of a pathogen’s RNR function.
In order to examine activity on a specific enzyme
more effectively, a molecule can be sought which
interacts with a specific protein, as was done for the
human insulin receptor (IR) by Salituro et al. (2001)
[29]. By using a series of screens with intact hamster
cells containing the human IR protein, they were
able to screen a library of small molecules that bind
to the IR target. If the extract interacted with the IR,
it would trigger the phosphorylation and activation
of a tyrosine kinase, which in turn would show
activity on the substrate polyGlu:Tyr (4:1). In their
experiment, the fungal-derived small molecule de-
methylasterriquinone B-1 was found to activate the
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IR complex. Such a technique may prove useful to
search extensive chemical lists for specifically tar-
geted effects.
While these strategies can be used to test many
extracts for possible effects in specific pathways, a
significant limitation remains that each extract has
to be tested separately for its activity on different
pathways. This generally translates into the investig-
ation of one pathway at a time. When one considers
the large number of pathways in the cell that may be
affected by any given chemical, the number of
chemicals which can be isolated from a single plant,
and the number of plants that may be candidates for
research, the potential economic and labor cost of
these investigations quickly surpasses that which is
practically available. Without more efficient tech-
niques, research would be limited to a small subset
of the available candidates, significantly restricting
discovery of alternative treatments. Similarly, for
extracts that have multiple effects, many of these
effects could also be overlooked. As a further limit-
ation, many of these tests are done in vitro, and may
not apply to living cells/organisms. Factors such as
intracellular localization and concentration cannot
be accounted for. Thus, though in vitro effects may
be demonstrated, these effects may not have the
chance to occur within a cellular environment.
Modern Techniques in Drug Discovery
To improve the speed and efficiency of the screening
process, high-throughput techniques have been de-
veloped that examine many potential target sites for
a given extract in a single experiment. Such tech-
niques are designed to identify effects on several
biochemical pathways. Two such techniques are
DNA microarray and gene deletion array (GDA)
analyses.While reviewing these large-scale analyses,
it should be kept in mind that an increase in
throughput comes with an inherent risk. The less
time spent on a given test, the higher the risk for false
positives and negatives. Yet the value of screening
large numbers by high-throughput analysis of pos-
sible source candidates for drug research cannot be
overlooked.
Microarray Analysis
Differential expression of multiple genes with known
and unknown functions may be used to evaluate the
mode of action of antifungals. The idea is that genes,
or gene products, which are directly or indirectly
interacting with a bioactive compound, are differen-
tially expressed once the cell is challenged with a
biologically-active compound. Traditionally, gene
expression has been evaluated by analysing the
amount of a specific messenger RNA (mRNA)
present in the cell through a method called Northern
analysis. mRNA is synthesized through transcription
from a given gene in accordance with molecular in-
teractions within the cell that regulate whether tran-
scription should remain the same, increase or de-
crease. In Northern analysis, total mRNA is size
fractionated by gel electrophoresis and then immob-
ilized onto membranes. Labeled DNA probes are
subsequently used to hybridize and quantify the
abundance of a specific target mRNA. Although a
very precise method for measuring the mRNA levels
of a gene, Northern analysis is time consuming. Re-
cently, a large-scale probe-based gene expression
analysis technique called microarray analysis has
been developed which uses microchip technology to
miniaturize the probe-mRNA interaction and there-
fore maximizes the number of genes that can be
monitored simultaneously.
Microarrays are constructed by binding a series
of probes to a chip, thus generating a platform to
detect an array of target genes. The probes are gener-
ally composed of fluorescent-labeled complementary
DNA (cDNA) molecules derived from messenger
RNA (mRNA). They bind to complementary short
sequences of target DNAs from those genes that are
arrayed on the chip. Total mRNA is isolated from
cells that are challenged by an antifungal compound.
As a control, mRNA is isolated from cells that are
untreated. The experimental and control mRNAs are
separately converted into cDNA through the action
of reverse transcriptase and differentially labeled
with fluorescent tags. The cDNAs are then mixed
together and applied to the surface of the chips. The
hybridization of the probes to the target DNA spots
are then visualized and quantified by a scanning
fluorescence array reader. Analysis of the data can
indicate whether transcription of any given gene is
altered under the experimental conditions. The inter-
pretation of the data can in turn be used to reveal
information about the target site and the mechanism
of the action of the antifungal. Depending on the
mode of action of an antifungal, if a given gene
product is a target site of the antifungal then it might
be expected that the treatment of the cells with that
antifungal would result in a significant change in the
expression of that particular gene. In this way the
cell may compensate for perturbations in particular
pathways. To investigate antifungal compounds,
chips arrayed with all Open Reading Frames (ORFs,
i.e. putative protein coding genes) of the brewer’s
yeast, Saccharomyces cerevisiae, are often used. The
simple life cycle, short duplication time and the well-
developed genetics associated with this yeast have
made it an ideal choice for follow up experiments.
ProteinMicroarrays, in early development stages,
can also be constructed using proteins as the targets,
to test for the binding of small molecules [30]. This
would allow for a quick determination of a chemic-
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al’s binding site within a cell, and would also reveal
if the chemical in question binds to multiple protein
targets. Within a single test, and on a single chip,
hundreds of thousands of binding assays can take
place, permitting the quick identification of a drug’s
effect.
A significant limitation of microarrays is the inter-
pretation of the large amount of data that it produces.
Variation in gene expression between different trials
together with a high rate of false positives can signi-
ficantly complicate the interpretation of the data. As
a result, various statistical tools have been developed
to help with the analysis of microarray data. To date,
however, the interpretation of microarray data re-
mains a significant challenge for biologists as well
as bioinformaticians.
Another significant drawback of the microarray
is that it is based on an indirect correlation; a positive
correlation does not necessarily specify a direct inter-
action. An increase in expression for gene “a” might
indicate that the antifungal is deactivating the gene
product “A” and as a response, the cell is producing
more of “A”. Alternatively, it is as likely that the
antifungal is interacting with gene product “B”
which, in turn, has an effect on genes “a, c, d, e...”.
Such a drawback of microarray analysis might be
compensated by a more direct method that targets
the activity of a gene product and not its expression
(see below).
Gene Deletion Array Analysis
The Gene Deletion Array (GDA) analysis is a high-
throughput in vivo technique that can be used to
elucidate the mechanism by which a bioactive com-
pound affects the cell. It works on a basis similar to
that of Synthetic Genetic Array (SGA) analysis. The
assumption in SGA analysis is that in a cell there
exist multiple overlapping pathways leading to a
single outcome [31]. The inactivation of one pathway
may not have a significant effect on the growth of
the cell. However when the first mutation is com-
bined with the inactivation of a second overlapping
pathway, this can lead to a growth defect. This
growth defect is termed “synthetic sick phenotype”.
In SGA, the inactivation of the second pathway is
generated via a specific gene deletion. In GDA,
however, the synthetic sick phenotype results from
the combination of a specific gene deletion and a
chemical interaction. GDA can be used, therefore,
to study the pathway and/or components affected by
a specific chemical.
Figure 3: Images Taken of Two Sample Plates from GDA Analysis, Testing for the Effects of an Extract of
Echinaceae on S. cerevisiae Gene Knock-out Mutants. While most of the Colonies show Comparable Growth,
some Knockout Mutant Colonies do not Grow Substantially in the presence of the Extract (circled Colonies on
Experimental Plate). The Analysis of the Specific GeneMutations in “Supersensitive” Colonies provides insight
into the Biochemical and Genetic Bases of the inhibitor mode-of-Action
Large-scale GDA analysis uses an array of yeast
mutant strains, each strain having a single gene
knocked out (Figure 3). In the case of S. cerevisiae,
there are approximately 4700 (of ~6000) genes that
can be deleted without affecting the viability of the
cell. To determine the mechanism by which a plant
extract affects yeast growth, an equal amount of in-
oculum from each mutant strain is transferred from
a master plate of gene knock-out strains to a plate
containing a concentration of the plant extract that
is slightly inhibitory to the growth of yeast. A second
plate, with no inhibitor added, is also inoculated with
all yeast mutants as a control. The inoculation pro-
cedure is usually done using an automated pinning
robot. After incubation and colonies are observed on
the plates, the size of each knock-out colony on the
experimental (with inhibitor) and control (no inhibit-
or) plates is estimated. Any significant growth reduc-
tion of a specificmutant colony on the plate contain-
ing the target plant extract is scored as a potential
hit. Colony size is tightly correlated to number of
cells in a colony and, thus, cell-division rates [32].
Once such colonies are identified, increased sensitiv-
ity to the compound can be verified by analysis of
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the Minimum Inhibitory Concentration (MIC), and
the function of the deleted genes and the pathways
in which they are involved can be used to shed light
on the mode of action by the plant extract. As most
pathways involve multiple different gene products,
there should be multiple hits on the same pathway.
If genes from two independent pathways show re-
duced growth, it will be interpreted that the extract
affects both pathways.
A significant limitation of GDA analysis is its re-
latively high rate of false positives. To minimize
these, multiple replicates must be conducted, which
results in the consumption of additional material that
is not always available. GDA data analysis provides
another difficulty. Comparing the growth of individu-
al colonies by eye, particularly if the colonies show
unequal growth within or between plates, can be te-
dious and unreliable. As a result, digital imaging
software that analyses colony size and growth pat-
terns can significantly improve the efficiency of
analysis. An automated system can compensate for
the universally reduced growth on a plate containing
sub-MIC levels of extract as compared to the control
plate. Statistical analysis can then be performed to
evaluate the growth of a specific colony in relation
to the average growth on both control and experiment-
al plates.
Another key difficulty with GDA lies in allocating
genes to specific pathways within the cell. At this
time, many genes have unknown functions. Many
others have multiple functions within the cell, and
could perform tasks for more than one pathway. For
example, a known DNA polymerase could be in-
volved in DNA synthesis, DNA repair, or both.
Likewise, while RNR catalyzes the formation of
DNA precursors, it may have other roles in the cell,
including spindle pole nucleation [33]. If the genes
shown to interact with the extract do not have a clear
function, have more than a single role to play in the
cell, or appear unrelated, the picture created by GDA
may very quickly become unclear.
High Throughput Screening
In many cases, pharmaceutical companies utilize
high-throughput screening to determine biologically
active fractions or mechanisms of antifungal activity.
With these emerging technologies, pharmaceutical
companies are now returning to the study of plant
derived drugs as 10,000 to 100,000 extracts can be
screened per day. Online HPLC combines HPLC
fractionation with biochemical assays and spectral
analysis such as GCMS [7]. Currently, systems that
examine drug-cell interactions exist. For example,
in an attempt to identify compounds that reduce dis-
eases such as breast cancer and osteoporosis, a plant
extract library containing 9888 different extracts was
examined for potential activities against estrogen
receptors. Of the 9888 extracts analysed, roughly
1100 hits were observed to interact with the estrogen
receptor [7]. Therefore, only 11.1% of all extracts
could be examined, reducing the amount of time
spent on studying inactive fractions. This technology
could be implemented to screen for new antifungal
drugs by screening antifungal activity against a lib-
rary of drug-resistant, drug-sensitive and opportun-
istic fungal strains. In addition, a specific antifungal
mechanism may be identified for study using high
throughput screening. Such a biochemical assay
could be developed as described above, which would
allow determination of extracts active against fungal
specific pathways, for example, cell wall (chitin)
biosynthesis.
Conclusion
While the importance and usefulness of many tradi-
tional medicines cannot be denied, only recently have
the required technologies become available to evalu-
ate these remedies and their effects in an efficient
and comprehensive manner. By examining the past
use of a given plant in the treatment of infections,
phytochemicals can be identified that inhibit fungal
pathogens. Moreover, with modern high-throughput
technologies such as online HPLC, DNA microar-
rays, GDA, and advances in robotics allowing test
automation, the exact effects of a given extract, as
well as the chemical or chemicals at work can also
be determined. Identification of these chemicals
provides leads for the synthesis of analogs and devel-
opment of novel antifungal drugs. Alternatively,
identification of active principles in traditional
medicines can also lead to standardization and quality
control of these materials. They can then be more
quickly registered under the “traditional use”
guidelines as lower cost natural health products
which are effective in both developing and developed
countries.
References
1. Alexander, B.D. and Perfect J.R. 1997. Antifungal resistance trends towards the year 2000. Implications for therapy and
new approaches. Drugs. 54: 657-678.
2. Arnason, J.T., Hebda, R., and Johns, T. 1981. Use of plants for food and medicine by native peoples of eastern Canada.
Canadian Journal of Botany. 59: 2189–2325.
3. Anderson, J.B. 2005. Evolution of antifungal drug resistance: mechanisms and pathogen fitness. Nature Reviews. 3: 547-
556.
INTERNATIONAL JOURNAL OF TECHNOLOGY, KNOWLEDGE AND SOCIETY, VOLUME 2
4. Soejarto D.D., Fong, H.H.S., Tan, G.T., et al. 2005. Ethnobotany/ethnopharmacology and mass bioprospecting: Issues
on intellectual property and benefit-sharing. Journal of Ethnopharmacology. 100: 15-22.
5. Jones, N.P., Arnason, J.T., Abou-Zaid, M., Akpagana, K., Sanchez-Vindas, P., and Smith, M.L. 2000. Antifungal activity
of extracts frommedicinal plants used by First Nations Peoples of eastern Canada. Journal of Ethnopharmacology.
73: 191-198.
6. Omar, S., Lemonnier, B., Jones, N., Ficker, C., Smith, M.L., Neema, C., Towers, G.H.N., Goel, K., and Arnason, J.T.
2000. Antimicrobial activity of extracts of eastern North America hardwood trees and relation to traditional
medicine. Journal of Ethnopharmacology.73: 161-170.
7. Van Elswijk, D.A. and Irth, H. 2003. Analytical tools for the detection and characterization of biologically active compounds
from nature. Phytochemisty Reviews. 1: 427-439.
8. Treyvaud-Amiguet, V. 2005 Ethnobotanical and phytochemical investigation of Central American flora. Ph. D. Thesis.
University of Ottawa, Ottawa, Ontario, Canada.
9. Brun, S., Berges, T., Poupard, P., Vauzelle-Moreau, C., Renier, G., Chabasse, D., Bouchara, J. P. (2004).Â Mechanisms
of azole resistance in petite mutants of Candida Glabrata. Antimicrobial Agents and Chemotherapy. 48: 1788-
1796.
10. Jensen-Pergakes, K.L., Kennedy, M.A., Lees, N.D., Baybuch, R., Koegel, C., and Bard, M. 1998. Sequencing, disruption,
and characterization of the Candida albicans sterol methyltransferase (ERG6) gene: drug susceptibility studies in
erg6 mutants. Antimicrobial Agents and Chemotherapy. 42:1160-1167.
11. Merali, S., Binns, S., Paulin-Levasseur, M., Ficker, C., Smith, M., Baum, B., Brovelli, E., and Arnason, J.T. 2003. An-
tifungal and anti-inflammatory activity of the genus Echinacea. Pharmaceutical Biology. 41: 412-420.
12. Ficker, C., Smith, M.L., Akpagana, K., Gbeassor, M., Zhang, J., Durst, T., R. Assabgui, R., and Arnason, J.T. 2003b.
Bioassay-guided isolation and identification of antifungal compounds from ginger. Phytotherapy Research. 17:
897-902.
13. Bennett, J.W., and Klich, M. 2003. Mycotoxins. Clinical Microbiology Reviews. 16:497-516.
14. Hof, H. 2001. Critical annotations to the use of azole antifungals for plant protection. Antimicrobial agents and chemo-
therapy. 45: 2987-2990.
15. Ficker, C.E., Smith, M.L., Susuarti, S., Leaman, D.J., Irawati, C., and Arnason, J.T. 2003. Inhibition of human patho-
genic fungi bymembers of Zingiberaceae used by the Kenyah (Indonesian Borneo). Journal of Ethnopharmacology.
85: 289-293.
16. Chandrasekaran, M., and Venkatesalu, V. 2004. Antibacterial and antifungal activity of Syzygium jambolanum seeds.
Journal of Ethnopharmacology. 91: 105-108.
17. Cowan, M.M. 1999. Plant products as antimicrobial agents. Clinical Microbiology Reviews. 12:564-582.
18. Binns, S.E., Purgina, B., Bergeron, C., Smith, M.L., Ball, L., Baum, B.R. and Arnason, J.T. 2000. Light-mediated anti-
fungal activity of Echinacea extracts. Planta Medica. 66:241-244.
19. Lopes, N.P., Kato, M.J., and Yoshida, M. 1999. Antifungal constituents from roots of Virola surnamensis. Phytochemistry.
51: 29-33.
20. Stermitz, F.R., Lorenz, P., Tawara, J.N., Zenewicz, L.A., and Lewis, K. 2000. Synergy in a medicinal plant: antimicro-
bial action of berberine potentiated by 5’-methoxyhydnocarpin, a multidrug pump inhibitor. Proceedings of the
National Academy of Science. 97: 1433-1437.
21. Bafi-Yeboa, N.F.A., Arnason, J.T., Baker, J., and Smith, M.L. 2005. Antifungal constituents of Northern prickly ash,
Zanthoxylum americanumMill. Phytomedicine. 12: 370-377.
22. Binns, S.E., Purgina, B., Bergeron, C., Smith, M.L., Ball, L., Baum, B.R. and Brun, S., Berge, T., Poupard, P., Vauzelle-
Moreau, C., Renier, G., Chabasse, D., and Bouchara, Jean-Philippe. 2004. Mechanisms of azole resistance in
petite mutants of Candida glabrata. Antimicrobial agents and chemotherapy. 48:1788-1796.
23. Ficker, C.E., Arnason, J.T., Vindas, P.S., Alvarez, L.P., Akpagana, K., Gbeassor, M., De Souza, C., and Smith, M.L.
2003a. Inhibition of human pathogenic fungi of ethnobotanically selected plant extracts.Mycoses. 46: 29-37.
24. Yang, X., Summerhurst, D.K., Koval, S.F., Ficker, C., Smith, M.L. and Bernards, M.A. 2001. Isolation of an antimicro-
bial compound from Impatiens balsamina L. using bioassay-guided fractionation. Phytotherapy Research. 15:
676-680.
25. Smith, M.L. Gregory, P., Bafi-Yeboa, N.F.A. and Arnason, J.T. 2004. Inhibition of DNA polymerization and antifungal
specificity of furanocoumarins present in traditional medicines. Phytochemistry and Photobiology. 79: 506-509.
26. Stenman, J., Finne, P., Stahls, A., Grenman, R., Stenman, U. H., Palotie, A., Orpana, A. 1999. Accurate determination
of relative messenger RNA levels by RT-PCR. Nature Biotechnology. 17: 720-722
27. Jong, A. Y., Yu, K., Zhou, B., Frgala, T., Reynolds, C. P., Yen, Y. 1999. A simple and sensitive ribonucleotide reductase
assay. Journal of Biomedical Science. 5: 62-68.
28. Fontecave, M., Lepoivre, M., Elleingand, E., Gerez, C., and Guittet, O. 1998. Resveratrol, a remarkable inhibitor of
ribonucleotide reductase. FEBS Letters. 421: 277-279.
29. Salituro, G. M., Pelaez, F., and Zhang, B.B. 2001. Discovery of a small molecule insulin receptor activator. Recent
Progress in Hormone Research. 56: 107-126.
30. MacBeath, G., and Schreiber, S.L. 2000. Printing proteins as microarraysfor high-throughput function determination.
Science. 289: 1760–1763.
31. Tong, A.H.Y., Lesage, G., Bader, G.D., et al 2004. Global mapping of the yeast genetic interaction network. Science.
303: 808-813.
JESSULAT, SMITH, MIR-RASHED, GOLSHANI, ARNASON, SMITH
32. Xu, J., Vilgalys, R., and Mitchell, T.G. 1998. Colony size can be used to determine the MIC of fluconazole for patho-
genic yeasts. Journal of Clinical Microbiology. 36: 2383-2385.
33. Takada, S., Shibata, T., Hiraoka, Y., and Masuda, H. 2000.Identification of Ribonucleotide Reductase Protein R1 as an
Activator of Microtubule Nucleation in Xenopus Egg Mitotic Extracts.Molecular Biology of the Cell. 11: 4173-
4187.
About the Authors
Matthew G. M. Jessulat
Research using yeast Gene Deletion Arrays to understand pathways involving genetic recombination and anti-
fungal inhibitors.
Robert Phillip Smith





Dr John Thor Arnason
University of Ottawa, Canada
Dr. Myron L. Smith
Carleton University, Canada
INTERNATIONAL JOURNAL OF TECHNOLOGY, KNOWLEDGE AND SOCIETY, VOLUME 2





Bill Cope, University of Illinois, Urbana-Champaign, USA. 
Mary Kalantzis, University of Illinois, Urbana-Champaign, USA. 




EDITORIAL ADVISORY BOARD 
Darin Barney, McGill University, Montreal, Quebec, Canada. 
Amy Besnoy, Copley University, University of San Diego, CA, USA. 
Marcus Breen, Northeastern University, Boston, USA. 
G.K. Chadha, Jawahrlal Nehru University, India. 
Simon Cooper, Monash University, Australia. 
Bill Dutton, University of Oxford, United Kingdom. 
David Hakken, University of Indiana, Bloomington, Indiana, USA. 
Michele Knobel, Montclair State University, New Jersey, USA. 
Chris Scanlon, RMIT University, Melbourne, Australia. 
Jeannette Shaffer, Edtech Leaders, VA, USA. 
Ravi S. Sharma, Nanyang Technological University, Singapore. 
Robin Stanton, Australian National University, Canberra, Australia. 
Telle Whitney, Anita Borg Institute for Women and Technology. 




Please visit the Journal website at http://www.Technology-Journal.com for further 
information: 
- ABOUT the Journal including Scope and Concerns, Editors, Advisory Board, 
Associate Editors and Journal Profile 
- FOR AUTHORS including Publishing Policy, Submission Guidelines, 





The Journal offers individual and institutional subscriptions. For further information please 
visit http://ijt.cgpublisher.com/subscriptions.html. Inquiries can be directed to 
subscriptions@commongroundpublishing.com  
 
 
 
INQUIRIES 
Email: cg-support@commongroundpublishing.com 
 
